{"id":"vintafolide","rwe":[],"tags":[{"label":"vintafolide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01CA06","category":"atc"},{"label":"Active","category":"status"},{"label":"Malignant epithelial tumor of ovary","category":"indication"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"vynfinit","offLabel":[],"synonyms":["vintafolide","EC145","vynfinit"],"timeline":[],"approvals":[],"brandName":"Vynfinit","ecosystem":[{"indication":"Malignant epithelial tumor of ovary","otherDrugs":[{"name":"bevacizumab","slug":"bevacizumab","company":"Genentech"},{"name":"niraparib","slug":"niraparib","company":"Tesaro Inc"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"vintafolide","explanation":"Imagine a special delivery system that targets cancer cells by binding to a specific receptor on their surface. This receptor is more common in cancer cells than normal cells, so the delivery system can selectively target and kill the cancer cells. This targeted approach helps minimize harm to healthy cells and reduce side effects.","oneSentence":"Vynfinit works by binding to folate receptor beta, which is overexpressed in certain cancer cells, and delivering a toxic payload to these cells.","technicalDetail":"Vintafolide is a folate receptor beta-targeting agent that utilizes a folate analog to deliver a toxic payload to cancer cells overexpressing folate receptor beta, leading to cell death and potential tumor regression."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4831","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=VINTAFOLIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VINTAFOLIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T16:09:25.632556","biosimilars":[],"competitors":[{"drugName":"vinblastine","drugSlug":"vinblastine","fdaApproval":"1965-11-05","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vincristine","drugSlug":"vincristine","fdaApproval":"1963-07-10","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vinorelbine","drugSlug":"vinorelbine","fdaApproval":"1994-12-23","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"vintafolide","indications":{"approved":[{"name":"Malignant epithelial tumor of ovary","source":"DrugCentral","snomedId":254849005,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"vinblastine","brandName":"vinblastine","genericName":"vinblastine","approvalYear":"1965","relationship":"same-class"},{"drugId":"vincristine","brandName":"vincristine","genericName":"vincristine","approvalYear":"1963","relationship":"same-class"},{"drugId":"vinorelbine","brandName":"vinorelbine","genericName":"vinorelbine","approvalYear":"1994","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01170650","phase":"PHASE3","title":"Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)","status":"TERMINATED","sponsor":"Endocyte","startDate":"2011-04-22","conditions":["Ovarian Cancer"],"enrollment":441,"completionDate":"2015-09-08"},{"nctId":"NCT01002924","phase":"PHASE2","title":"Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)","status":"COMPLETED","sponsor":"Endocyte","startDate":"2009-12-31","conditions":["Solid Tumors"],"enrollment":1,"completionDate":"2013-12-11"},{"nctId":"NCT01577654","phase":"PHASE2","title":"Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Endocyte","startDate":"2011-03","conditions":["Non Small Cell Lung Cancer"],"enrollment":203,"completionDate":"2015-08"},{"nctId":"NCT00511485","phase":"PHASE2","title":"Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)","status":"COMPLETED","sponsor":"Endocyte","startDate":"2007-08","conditions":["Adenocarcinoma of the Lung"],"enrollment":43,"completionDate":"2009-11"},{"nctId":"NCT01688791","phase":"PHASE1","title":"A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)","status":"TERMINATED","sponsor":"Endocyte","startDate":"2012-12","conditions":["Advanced Cancer"],"enrollment":37,"completionDate":"2014-09"},{"nctId":"NCT02049281","phase":"PHASE1","title":"A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)","status":"TERMINATED","sponsor":"Endocyte","startDate":"2014-02","conditions":["Solid Tumor"],"enrollment":3,"completionDate":"2014-05"},{"nctId":"NCT00507741","phase":"PHASE2","title":"Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)","status":"COMPLETED","sponsor":"Endocyte","startDate":"2007-08","conditions":["Ovarian Cancer","Endometrial Cancer"],"enrollment":49,"completionDate":"2009-04"},{"nctId":"NCT00722592","phase":"PHASE2","title":"Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)","status":"COMPLETED","sponsor":"Endocyte","startDate":"2008-09","conditions":["Ovarian Cancer"],"enrollment":162,"completionDate":"2012-12"},{"nctId":"NCT00308269","phase":"PHASE1","title":"Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)","status":"COMPLETED","sponsor":"Endocyte","startDate":"2006-03","conditions":["Cancer"],"enrollment":32,"completionDate":"2008-07"},{"nctId":"NCT01953536","phase":"PHASE2","title":"Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)","status":"WITHDRAWN","sponsor":"Endocyte","startDate":"2014-04","conditions":["Breast Neoplasms"],"enrollment":0,"completionDate":"2016-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"36O410ZD4I","CHEBI":"CHEBI:134736","INN_ID":"9564","UMLSCUI":"C3530172","ChEMBL_ID":"CHEMBL3039521","KEGG_DRUG":"D10434","DRUGBANK_ID":"DB05168","PUBCHEM_CID":"25014653","MESH_SUPPLEMENTAL_RECORD_UI":"C520389"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":30,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01CA06","allCodes":["L01CA06"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Vynfinit (VINTAFOLIDE) is a small molecule drug in the vintafolide class, originally developed by and currently owned by a pharmaceutical company. It is approved to treat malignant epithelial tumors of the ovary. The commercial status of Vynfinit is not specified, but it is likely patented. Key safety considerations include unknown half-life, bioavailability, and potential side effects. Further research is needed to fully understand its pharmacology and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}